| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | Ames |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | Ames |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | Ames |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Phase 2 | SWOG Cancer Research Network | Ames |
| A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | Ames |
| A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | Phase 3 | AstraZeneca | Ames |
| A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | Ames |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | Ames |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | Ames |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | Ames |
| Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects | — | Alliance for Clinical Trials in Oncology | Ames |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | Ames |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | Ames |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin | Phase 3 | NRG Oncology | Ames |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | Ames |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | Ames |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | Ames |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | Ames |
| High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | Ames |
| Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | — | SWOG Cancer Research Network | Ames |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | Ames |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | Ames |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | Ames |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | Ames |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | Ames |
| RESISTance Exercise for Depression Trial | N/A | University of Wisconsin, Madison | Ames |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | Ames |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | Ames |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Phase 3 | BioNTech SE | Ames |
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) | Phase 3 | AstraZeneca | Ames |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | Ames |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | Ames |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | Ames |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | Ames |
| Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | N/A | Alliance for Clinical Trials in Oncology | Ames |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Ames |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Ames |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase 2 | Alliance for Clinical Trials in Oncology | Ames |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | Phase 3 | Alliance for Clinical Trials in Oncology | Ames |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial | Phase 3 | Alliance for Clinical Trials in Oncology | Ames |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | Ames |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | Ames |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | Ames |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | Phase 3 | National Cancer Institute (NCI) | Ames |
| Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL | Phase 3 | Alliance for Clinical Trials in Oncology | Ames |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | Ames |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | Phase 3 | Alliance for Clinical Trials in Oncology | Ames |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | Ames |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | Ames |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | Ames |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | Ames |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | Ames |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Phase 2 | NRG Oncology | Ames |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Phase 2 | National Cancer Institute (NCI) | Ames |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | Phase 2 | National Cancer Institute (NCI) | Ames |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | Ames |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | Phase 2 | National Cancer Institute (NCI) | Ames |
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | Phase 3 | National Cancer Institute (NCI) | Ames |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | Ames |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | NRG Oncology | Ames |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | Ames |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | Ames |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | Phase 2 | SWOG Cancer Research Network | Ames |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | Ames |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | Ames |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | Ankeny |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | Ankeny |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | Ankeny |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | Ankeny |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | Ankeny |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | Ankeny |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | Ankeny |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Ankeny |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | Phase 3 | SWOG Cancer Research Network | Ankeny |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers | — | ECOG-ACRIN Cancer Research Group | Ankeny |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | Ankeny |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | Ankeny |
| Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | Phase 3 | SWOG Cancer Research Network | Ankeny |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | Ankeny |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | Ankeny |
| Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer | — | Wake Forest University Health Sciences | Ankeny |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | Ankeny |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | Ankeny |
| Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer | Phase 3 | Canadian Cancer Trials Group | Ankeny |
| Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | Phase 3 | Alliance for Clinical Trials in Oncology | Ankeny |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Phase 2 | SWOG Cancer Research Network | Ankeny |
| Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Phase 3 | ECOG-ACRIN Cancer Research Group | Ankeny |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma | Phase 3 | NRG Oncology | Ankeny |
| Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | Ankeny |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | Ankeny |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Phase 3 | NRG Oncology | Ankeny |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | Ankeny |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer | N/A | Alliance for Clinical Trials in Oncology | Ankeny |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | Phase 2 | Alliance for Clinical Trials in Oncology | Ankeny |
| Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | Phase 2 | Alliance for Clinical Trials in Oncology | Ankeny |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Phase 3 | National Cancer Institute (NCI) | Ankeny |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Ankeny |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | Ankeny |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | Bettendorf |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | Bettendorf |
| Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | Phase 3 | Alliance for Clinical Trials in Oncology | Carroll |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | Cedar Rapids |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | Phase 3 | SWOG Cancer Research Network | Cedar Rapids |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease | Phase 3 | BeOne Medicines | Cedar Rapids |
| Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) | N/A | ECOG-ACRIN Cancer Research Group | Cedar Rapids |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | Cedar Rapids |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy | Phase 2 | National Cancer Institute (NCI) | Cedar Rapids |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02) | Phase 2/3 | BioNTech SE | Cedar Rapids |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | Cedar Rapids |
| Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study | — | Wake Forest University Health Sciences | Cedar Rapids |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body | Phase 3 | SWOG Cancer Research Network | Cedar Rapids |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse | Phase 2 | National Cancer Institute (NCI) | Cedar Rapids |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | Cedar Rapids |
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Phase 3 | UroGen Pharma Ltd. | Clive |
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | Phase 3 | SWOG Cancer Research Network | Clive |
| Family Communications After Genetic Testing | N/A | Alliance for Clinical Trials in Oncology | Clive |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | Clive |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | Clive |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | Clive |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | Clive |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | Clive |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | Council Bluffs |
| AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications | Phase 3 | Novo Nordisk A/S | Council Bluffs |
| Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | Phase 2 | SWOG Cancer Research Network | Council Bluffs |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | Council Bluffs |
| Integrated Cancer Repository for Cancer Research | — | University of Nebraska | Council Bluffs |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Phase 2 | National Cancer Institute (NCI) | Council Bluffs |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease | Phase 3 | Exelixis | Council Bluffs |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Phase 3 | Novo Nordisk A/S | Davenport |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | Davenport |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | Des Moines |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | Des Moines |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | Des Moines |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Phase 3 | AstraZeneca | Des Moines |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | Phase 3 | Shanghai Henlius Biotech | Des Moines |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) | Phase 3 | Children's Oncology Group | Des Moines |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | Des Moines |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | Des Moines |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | Des Moines |
| A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) | Phase 3 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Des Moines |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | Des Moines |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | Des Moines |
| A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | Phase 3 | AstraZeneca | Des Moines |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | Des Moines |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | Des Moines |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | Des Moines |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | Des Moines |
| A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | Phase 2 | Teligene US | Des Moines |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Phase 3 | AbbVie | Des Moines |
| A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer | Phase 1 | TerSera Therapeutics LLC | Des Moines |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | Des Moines |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | Des Moines |
| Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital | N/A | Fisher and Paykel Healthcare | Des Moines |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | Des Moines |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | Des Moines |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | Des Moines |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | Des Moines |
| Quality of End-of-Life Care for Children With Cancer | — | Children's Oncology Group | Des Moines |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | Des Moines |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | Phase 3 | Canadian Cancer Trials Group | Des Moines |
| Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | Phase 2 | AstraZeneca | Des Moines |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | Phase 2 | AbbVie | Des Moines |
| Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial | Phase 3 | Alliance for Clinical Trials in Oncology | Des Moines |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | Des Moines |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | Des Moines |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | Des Moines |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | Des Moines |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | Des Moines |
| Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women | N/A | M.D. Anderson Cancer Center | Des Moines |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia | Phase 3 | Children's Oncology Group | Des Moines |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Phase 3 | Cogent Biosciences, Inc. | Iowa City |
| 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry | Phase 2 | University of Iowa | Iowa City |
| 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | Phase 1 | Mohammed Milhem | Iowa City |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Phase 3 | Merck Sharp & Dohme LLC | Iowa City |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | Iowa City |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | Phase 1/2 | BioNTech SE | Iowa City |
| A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | Phase 1/2 | BeOne Medicines | Iowa City |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | Phase 1 | Kyowa Kirin, Inc. | Iowa City |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | Iowa City |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Sanofi | Iowa City |
| A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies | — | Tempus AI | Iowa City |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | Iowa City |
| A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | — | argenx | Iowa City |
| A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | Phase 1 | Immunome, Inc. | Iowa City |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | Iowa City |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) | Phase 1 | AstraZeneca | Iowa City |
| A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) | Phase 2 | NSABP Foundation Inc | Iowa City |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | Iowa City |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune, Inc. | Iowa City |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | Phase 3 | Novo Nordisk A/S | Iowa City |
| A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | Phase 1 | CRISPR Therapeutics | Iowa City |
| A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System | N/A | Biosense Webster, Inc. | Iowa City |
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | Phase 3 | AstraZeneca | Iowa City |
| A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | Iowa City |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | Iowa City |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | Hoffmann-La Roche | Iowa City |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | Iowa City |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | Iowa City |
| A Study of ASP1002 in Adults for Treatment of Solid Tumors | Phase 1 | Astellas Pharma Global Development, Inc. | Iowa City |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | Iowa City |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | Iowa City |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | Iowa City |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults | Phase 3 | Eli Lilly and Company | Iowa City |
| A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) | Phase 2 | Merck Sharp & Dohme LLC | Iowa City |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | Phase 1 | Cullinan Therapeutics Inc. | Iowa City |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | Iowa City |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Phase 3 | GlaxoSmithKline | Iowa City |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | Iowa City |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Phase 3 | GlaxoSmithKline | Iowa City |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 2 | Incyte Corporation | Iowa City |
| A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | Iowa City |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Phase 2 | Kymera Therapeutics, Inc. | Iowa City |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | Phase 1 | Eli Lilly and Company | Iowa City |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | Iowa City |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | Iowa City |
| A Study of Methylprednisolone in People Having Liver Surgery | Phase 3 | Memorial Sloan Kettering Cancer Center | Iowa City |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | Phase 2 | Nurix Therapeutics, Inc. | Iowa City |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | Iowa City |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | Iowa City |
| A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | Iowa City |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | Iowa City |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | Iowa City |
| A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma | Phase 1/2 | TORL Biotherapeutics, LLC | Iowa City |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | Iowa City |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Phase 3 | Zai Lab (Shanghai) Co., Ltd. | Iowa City |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | Iowa City |
| A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | Iowa City |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Phase 1 | Aktis Oncology, Inc. | Iowa City |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Phase 3 | Children's Oncology Group | Iowa City |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection | Phase 1 | GigaGen, Inc. | Iowa City |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | Phase 3 | Celgene | Iowa City |
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma | Phase 3 | Corbus Pharmaceuticals Inc. | Iowa City |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Phase 2 | Janssen Research & Development, LLC | Iowa City |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Phase 3 | Hoffmann-La Roche | Iowa City |
| A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL | Phase 1/2 | GlaxoSmithKline | Iowa City |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | Iowa City |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | Hoffmann-La Roche | Iowa City |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | Iowa City |
| A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | Phase 2 | C4 Therapeutics, Inc. | Iowa City |
| A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | Iowa City |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | Iowa City |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | Iowa City |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | Iowa City |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | Phase 1/2 | Bristol-Myers Squibb | Iowa City |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeOne Medicines | Iowa City |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | Iowa City |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | Phase 1 | AstraZeneca | Iowa City |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | Iowa City |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Phase 1 | Allogene Therapeutics | Iowa City |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | Iowa City |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Phase 1 | Pfizer | Iowa City |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Hoffmann-La Roche | Iowa City |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Phase 2 | Boehringer Ingelheim | Iowa City |
| ATrial Tachycardia PAcing Therapy in Congenital Heart | — | Ian Law | Iowa City |
| AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | Phase 1/2 | AstraZeneca | Iowa City |
| Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) | Phase 4 | University of Illinois Chicago | Iowa City |
| Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | Phase 2 | Medical College of Wisconsin | Iowa City |
| Acceptance and Commitment Therapy for Patients Undergoing Coronary Artery Bypass Graft Surgery | N/A | University of Iowa | Iowa City |
| Activity Levels in Bone Marrow Transplant Patients | — | Michael Tomasson | Iowa City |
| Adenosine vs Diltiazem for Treatment of SVT in the ED | Phase 4 | Anne E. Zepeski | Iowa City |
| Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm | Phase 2 | Greg Durm, MD | Iowa City |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Phase 2 | Artiva Biotherapeutics, Inc. | Iowa City |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | Iowa City |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | Iowa City |
| BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | Phase 1 | BeOne Medicines | Iowa City |
| BOdygUardian MOnitoriNg for ReCurrencE of AF | — | Heart Rhythm Clinical and Research Solutions, LLC | Iowa City |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | Iowa City |
| Beat Childhood Cancer Specimen Banking and Data Registry | — | Giselle Sholler | Iowa City |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | Phase 2 | Merck Sharp & Dohme LLC | Iowa City |
| Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | — | M.D. Anderson Cancer Center | Iowa City |
| Breast Cancer PSMA PET | Early 1 | Ahmad Shariftabrizi | Iowa City |
| CHAMP Lung Cancer Screening Program | N/A | Jill Kolesar | Iowa City |
| Carbon Dioxide (CO2) Chemosensitivity and SUDEP | N/A | University of Iowa | Iowa City |
| Cell Free DNA in Cardiac Sarcoidosis | N/A | Nabeel Hamzeh | Iowa City |
| Cerebellar Stimulation and Cognitive Control | N/A | Krystal Parker, PhD | Iowa City |
| Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Phase 2 | Johns Hopkins University | Iowa City |
| Collection of Tissue Samples for Cancer Research | — | National Cancer Institute (NCI) | Iowa City |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Iowa City |
| Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment | Phase 2 | RTOG Foundation, Inc. | Iowa City |
| Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2 | — | University of Washington | Iowa City |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | Iowa City |
| Concurrent TMS-fMRI | N/A | Jing Jiang | Iowa City |
| Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders | N/A | Terry L. Wahls | Iowa City |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | Phase 1/2 | University of Utah | Iowa City |
| Diabetic Foot Ulcer Imaging- Study 2 | N/A | Linnea Polgreen | Iowa City |
| Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging | N/A | Natalie Denburg | Iowa City |
| E-Tailored Pain Management Support for Dementia Family Caregivers: Feasibility of the PACE-app | N/A | University of Iowa | Iowa City |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | Iowa City |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | Iowa City |
| Empagliflozin Treatment in Kidney Transplant Recipients | Phase 4 | VA Office of Research and Development | Iowa City |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | Iowa City |
| Exercise Oncology Clinic Pilot Feasibility Trial | N/A | Jess S. Gorzelitz | Iowa City |
| Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy | — | Photocure | Iowa City |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | Iowa City |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | Iowa City |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | Iowa City |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | Phase 2 | SCRI Development Innovations, LLC | Iowa City |
| GEMINI-NSCLC: NSCLC Biomarker Study | — | Tempus AI | Iowa City |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | Iowa City |
| High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) | Phase 1 | Kittika Poonsombudlert | Iowa City |
| Home-Based Monitoring in Parkinson's Disease | — | Jacob E. Simmering | Iowa City |
| ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | — | Stanford University | Iowa City |
| IH, Brain Health, and T2D | N/A | Darren P Casey | Iowa City |
| Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG | Phase 2 | CellSight Technologies, Inc. | Iowa City |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | Iowa City |
| Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer | Phase 2 | University of Kansas Medical Center | Iowa City |
| Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | Phase 2 | Michael A. O'Donnell | Iowa City |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | Iowa City |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens | Phase 3 | Servier Bio-Innovation LLC | Iowa City |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | Iowa City |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | Iowa City |
| KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | Phase 2 | Kumquat Biosciences Inc. | Iowa City |
| Ketamine Alcohol (in Treatment-Resistant Depression) | Phase 2 | Mark Niciu | Iowa City |
| Limited-duration Teclistamab | Phase 2 | Abramson Cancer Center at Penn Medicine | Iowa City |
| Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | Phase 3 | St. Louis University | Iowa City |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | Iowa City |
| Lurbinectedin in FET-Fused Tumors | Phase 1/2 | Children's Hospital of Philadelphia | Iowa City |
| MB-105 in Patients With CD5 Positive T-cell Lymphoma | Phase 2 | March Biosciences Inc | Iowa City |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | Phase 1/2 | Perspective Therapeutics | Iowa City |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer | Phase 2 | Hirva Mamdani | Iowa City |
| Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes | Early 1 | Anna Stanhewicz, PhD | Iowa City |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | Iowa City |
| Multi-Center Clean Air Randomized Controlled Trial in COPD | Phase 3 | JHSPH Center for Clinical Trials | Iowa City |
| Myriad™ Augmented Soft Tissue Reconstruction Registry | — | Aroa Biosurgery Limited | Iowa City |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | Iowa City |
| Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response | Phase 4 | University of Wisconsin, Madison | Iowa City |
| Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma | Phase 1 | Rina Plattner | Iowa City |
| Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | Phase 1/2 | Veronika Bachanova | Iowa City |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | Iowa City |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | Iowa City |
| Optimal Ventilation for Cardiac Arrest | N/A | Children's Hospital of Philadelphia | Iowa City |
| Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes | Early 1 | Anna Stanhewicz, PhD | Iowa City |
| PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department | — | University of Iowa | Iowa City |
| PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Phase 4 | Brigham and Women's Hospital | Iowa City |
| Paced Heart Rate Acceleration for Cardiac Conditioning | N/A | Denice Hodgson-Zingman, MD | Iowa City |
| Palbociclib and Pembrolizumab in Sarcoma | Phase 1 | John Rieth | Iowa City |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | Iowa City |
| Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program | — | Alnylam Pharmaceuticals | Iowa City |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | Iowa City |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | Iowa City |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | Phase 1 | Novartis Pharmaceuticals | Iowa City |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | Phase 2 | Weill Medical College of Cornell University | Iowa City |
| Physiology-directed Epinephrine Dosing in Pediatric Cardiac Arrest | — | Children's Hospital of Philadelphia | Iowa City |
| Preop Laxatives in Robotic Urologic Surgery | Phase 4 | Chad R. Tracy | Iowa City |
| Preventing Injured Knees From osteoArthritis: Severity Outcomes | Phase 2 | Brigham and Women's Hospital | Iowa City |
| Product Surveillance Registry | — | Medtronic | Iowa City |
| Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | Phase 2 | New Mexico Cancer Research Alliance | Iowa City |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | Iowa City |
| Quantitative MRI Assessment of Breast Cancer Therapy Response | — | Corewell Health East | Iowa City |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | Phase 2 | Academic and Community Cancer Research United | Iowa City |
| Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | Iowa City |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | Iowa City |
| Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium | N/A | Motif Neurotech, Inc. | Iowa City |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | Phase 2 | Oana Danciu | Iowa City |
| Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM | Early 1 | Anna Stanhewicz, PhD | Iowa City |
| SPIROMICS Study of Early COPD Progression (SOURCE) | — | University of Massachusetts, Worcester | Iowa City |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | Iowa City |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | Iowa City |
| Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | Phase 1 | Oxford BioTherapeutics Ltd | Iowa City |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | Iowa City |
| Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | Phase 1 | Orano Med Theranostics, SAS | Iowa City |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | Iowa City |
| Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers | Phase 2 | University of Iowa | Iowa City |
| Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma | Phase 1 | Christopher Strouse | Iowa City |
| Sitagliptin in Recurrent/Progressive Grade 4 Glioma | Phase 1 | Kailin Yang, MD, PhD | Iowa City |
| Sleep Apnea in Patients With MGUS and MM | — | Michael Tomasson | Iowa City |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Phase 3 | Corvus Pharmaceuticals, Inc. | Iowa City |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | Phase 1/2 | Phanes Therapeutics | Iowa City |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | Iowa City |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Phase 3 | Novartis Pharmaceuticals | Iowa City |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | Phase 3 | AstraZeneca | Iowa City |
| Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | Phase 1/2 | AstraZeneca | Iowa City |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Iowa City |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | Iowa City |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/2 | IDEAYA Biosciences | Iowa City |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Phase 1/2 | Inhibrx Biosciences, Inc | Iowa City |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | Iowa City |
| Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | Phase 2 | Dustin Deming | Iowa City |
| Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | Phase 1 | RayzeBio, Inc. | Iowa City |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | Phase 1/2 | Lyell Immunopharma, Inc. | Iowa City |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 | Takeda | Iowa City |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Phase 3 | TG Therapeutics, Inc. | Iowa City |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Phase 3 | Bausch Health Americas, Inc. | Iowa City |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Tango Therapeutics, Inc. | Iowa City |
| Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Phase 3 | Takeda | Iowa City |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | Iowa City |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | Iowa City |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Phase 2 | AstraZeneca | Iowa City |
| T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas | N/A | John M. Buatti | Iowa City |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | Iowa City |
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | Phase 1/2 | Perspective Therapeutics | Iowa City |
| Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | Phase 2 | Dwight Owen | Iowa City |
| Test-retest Evaluation of [18F]F-AraG PET | Phase 2 | CellSight Technologies, Inc. | Iowa City |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | Phase 1 | National Cancer Institute (NCI) | Iowa City |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | SWOG Cancer Research Network | Iowa City |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Iowa City |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Phase 2 | National Cancer Institute (NCI) | Iowa City |
| Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | Phase 3 | Eastern Cooperative Oncology Group | Iowa City |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | Iowa City |
| The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy | Phase 1 | Anna Stanhewicz, PhD | Iowa City |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | Iowa City |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | Iowa City |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 1/2 | Novartis Pharmaceuticals | Iowa City |
| Type 1 Diabetes Extension Study | — | National Institute of Allergy and Infectious Diseases (NIAID) | Iowa City |
| University of Iowa Interventional Psychiatry Service Patient Registry | — | Mark Niciu | Iowa City |
| Using Xe MRI to Guide Radiation Therapy for Lung Cancer | Phase 2 | Sean Fain | Iowa City |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Iowa City |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | Iowa City |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | Iowa City |
| A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | Sioux City |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | Sioux City |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase 2/3 | CSL Behring | Sioux City |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | Phase 3 | AstraZeneca | Waterloo |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | Waterloo |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Phase 3 | Eli Lilly and Company | Waterloo |
| A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | Phase 3 | Eli Lilly and Company | Waterloo |
| A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | Phase 3 | AstraZeneca | Waterloo |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | Waterloo |
| Tenapanor in Synucleinopathy-Related Constipation | Phase 2 | Cedar Valley Digestive Health Center | Waterloo |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | Waukee |
| A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Loxo Oncology, Inc. | Waukee |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | Waukee |
| A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | BeOne Medicines | Waukee |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Phase 3 | BeOne Medicines | Waukee |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | Waukee |
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | Phase 2 | Hoffmann-La Roche | Waukee |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | Waukee |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) | Phase 3 | Merck Sharp & Dohme LLC | West Des Moines |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | West Des Moines |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | West Des Moines |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Novo Nordisk A/S | West Des Moines |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | West Des Moines |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | West Des Moines |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | West Des Moines |
| A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Phase 3 | Eli Lilly and Company | West Des Moines |
| A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | West Des Moines |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | West Des Moines |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | West Des Moines |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | West Des Moines |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | West Des Moines |
| Encore PFO Closure Device - The PerFOrm Trial | N/A | Encore Medical Inc. | West Des Moines |
| Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation | N/A | Boston Scientific Corporation | West Des Moines |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | Phase 3 | Amgen | West Des Moines |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | West Des Moines |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | West Des Moines |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | West Des Moines |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | West Des Moines |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | West Des Moines |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Phase 3 | Novo Nordisk A/S | West Des Moines |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | West Des Moines |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | West Des Moines |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | West Des Moines |
| myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home | N/A | Temple University | West Des Moines |